Complement Component C3 Binds to the A3 Domain of von Willebrand Factor

• Main Authors: Jennifer G. Nolasco, Leticia H. Nolasco, Qi Da, Sonya Cirlos, Zaverio M. Ruggeri, Joel L. Moake, Miguel A. Cruz
• Format: Article
• Language: English
• Published: Georg Thieme Verlag KG 2018-07-01
• Series: TH Open
• Subjects: complement component c3; von willebrand factor; alternative complement pathway; thrombosis; inflammation
• Online Access: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1672189

von Willebrand factor (VWF) is a multimeric protein composed of monomeric subunits (∼280 kD) linked by disulfide bonds. During hemostasis and thrombosis, ultralarge (UL) VWF (ULVWF) multimers initiate platelet adhesion. In vitro, human C3 binds to ULVWF multimeric strings secreted by and anchored to human endothelial cell to promote the assembly and activation of C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) of the alternative complement pathway (AP). The purified and soluble C3 avidly binds to recombinant human VWF A1A2A3, as well as the recombinant isolated human VWF A3 domain. Notably, the binding of soluble human ULVWF multimers to purified human C3 was blocked by addition of a monovalent Fab fragment antibody to the VWF A3 domain. We conclude that the A3 domain in VWF/ULVWF contains a docking site for C3. In contrast, purified human C4, an essential component of the classical and lectin complement pathways, binds to soluble, isolated A1, but not to ULVWF strings secreted by and anchored to endothelial cells. Our findings should facilitate the design of new therapeutic agents to suppress the initiation of the AP on ULVWF multimeric strings during thrombotic and inflammatory disorders.